Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Advanced Cancer|Metastatic Cancer
DRUG: Q901|DRUG: KEYTRUDAÂ® (pembrolizumab)
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 28 days of cycle 1 (each cycle is 28 days)
Change in the area under curve (AUC) of Q901, Cycle 1 Day 1 and Day 22, Cycle 2 Day 8 and Day 22 (each cycle is 28 days)|Change in the maximum plasma concentration (Cmax) of Q901, Cycle 1 Day 1 and Day 22, Cycle 2 Day 8 and Day 22 (each cycle is 28 days)|Change in the time of maximum plasma concentration (Tmax) of Q901, Cycle 1 Day 1 and Day 22, Cycle 2 Day 8 and Day 22 (each cycle is 28 days)|Tumor response using RECIST version 1.1 throughout study, Baseline and at the end of every even cycle up to approximately 2 years (each cycle is 28 days)
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab